EFFECTS OF ROSIGLITAZONE ON COGNITION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT (MCI).
The purpose of this 20-month research study is to determine if improving the way insulin works to regulate blood sugar helps to improve memory in people with memory loss. For more information, please call the Kagan Treatment Development Program at (310) 794-6191.

BAPINEUZUMAB AS AN ANTI-ALZHEIMER’S THERAPY
This research study will examine the safety and effectiveness of bapineuzumab, an anti-Amyloid Beta antibody, on the progression of Alzheimer’s disease. The study involves 6 intravenous infusions of the investigational drug over the course of 11/2 years. For more information, please call the Kagan Treatment Development Program at (310) 794-6191.